TY - JOUR
T1 - Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma
AU - PICHI, FRANCESCO
AU - DOLZ-MARCO, R. O.S.A.
AU - FRANCIS, JASMINE H.
AU - AU, ADRIAN
AU - DAVIS, JANET L.
AU - FAWZI, AMANI
AU - GATTOUSI, SARRA
AU - GOLDSTEIN, DEBRA A.
AU - KEANE, PEARSE A.
AU - MISEROCCHI, ELISABETTA
AU - MARCHESE, ALESSANDRO
AU - OHNO-MATSUI, KYOKO
AU - SAGOO, MANDEEP S.
AU - SMITH, SCOTT D.
AU - SOBOL, ETHAN K.
AU - TASIOPOULOU, ANASTASIA
AU - YANG, XIAOLU
AU - SHIELDS, CAROL L.
AU - FREUND, K. BAILEY
AU - SARRAF, DAVID
N1 - Funding Information:
Financial disclosures: R.D.M. is a consultant to Heidelberg Engineering, she receives research support from Allergan, Genentech/Roche, and Novartis; D.S. is a consultant to Amgen, Bayer, Genentech, Iveric bio, Novartis, and Optovue and has received speaker fees from Optovue and research grants from Genentech, Heidelberg, Optovue, Regeneron and Topcon. K.B.F is a consultant to Genentech, Zeiss, Heidelberg Engineering, Allergan, Bayer, and Novartis. None of the other authors have any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing what is written in the submitted work.
Funding Information:
Funding and Support: This work was supported by the Research To Prevent Blindness Inc. (D.S.), New York NY and the Macula Foundation Inc. (D.S., K.B.F.), New York, New York, for the design and conduct of the study and the Cancer Center Support Grant (P30 CA008748) (F.J.H.) for collection, management, analysis, and interpretation of the data.
Funding Information:
Funding and Support: This work was supported by the Research To Prevent Blindness Inc. (D.S.), New York NY and the Macula Foundation Inc. (D.S. K.B.F.), New York, New York, for the design and conduct of the study and the Cancer Center Support Grant (P30 CA008748) (F.J.H.) for collection, management, analysis, and interpretation of the data. Financial disclosures: R.D.M. is a consultant to Heidelberg Engineering, she receives research support from Allergan, Genentech/Roche, and Novartis; D.S. is a consultant to Amgen, Bayer, Genentech, Iveric bio, Novartis, and Optovue and has received speaker fees from Optovue and research grants from Genentech, Heidelberg, Optovue, Regeneron and Topcon. K.B.F is a consultant to Genentech, Zeiss, Heidelberg Engineering, Allergan, Bayer, and Novartis. None of the other authors have any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing what is written in the submitted work. The principal investigator (Francesco Pichi) and the Senior Author (David Sarraf) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/6
Y1 - 2022/6
N2 - PURPOSE: Although diagnosing vitreoretinal lymphoma (VRL) can be challenging, early detection is critical for visual prognosis. We analyzed the spectrum of optical coherence tomography (OCT) findings in patients with biopsy-proven VRL and correlate these features with clinical parameters. DESIGN: This retrospective cross-sectional study was a multicenter chart review from 13 retina, uveitis, and ocular oncology clinics worldwide from 2008 to 2019. We included patients with a diagnosis of biopsy-proven VRL imaged with OCT at presentation. Ocular information, systemic information, and multimodal retinal imaging findings were collected and studied. The main outcome measure was the characteristics of VRL on OCT. RESULTS: A total of 182 eyes of 115 patients (63 women, mean age 65 years) were included in this study. The disease was bilateral in 81 patients (70%), and mean baseline visual acuity was 0.2 ± 0.89 logMAR (Snellen equivalent, 20/32). At baseline, 38 patients (33%) presented with isolated ocular involvement, 54 (45%) with associated central nervous system involvement, and 11 (10%) with other systemic lymphomatous involvement; an additional 12 patients (10%) presented with central nervous system and other systemic involvement. On OCT, tumor infiltration was identified in various retinal layers, including lesions in the subretinal pigment epithelium compartment (91% of eyes), the subretinal compartment (43% of eyes), and the intraretinal compartment (7% of eyes). OCT analysis of eyes with VRL identified 3 main regions of retinal infiltration. Subretinal pigment epithelium location, with or without subretinal infiltration, was the most common pattern of involvement and isolated intraretinal infiltration was the least.
AB - PURPOSE: Although diagnosing vitreoretinal lymphoma (VRL) can be challenging, early detection is critical for visual prognosis. We analyzed the spectrum of optical coherence tomography (OCT) findings in patients with biopsy-proven VRL and correlate these features with clinical parameters. DESIGN: This retrospective cross-sectional study was a multicenter chart review from 13 retina, uveitis, and ocular oncology clinics worldwide from 2008 to 2019. We included patients with a diagnosis of biopsy-proven VRL imaged with OCT at presentation. Ocular information, systemic information, and multimodal retinal imaging findings were collected and studied. The main outcome measure was the characteristics of VRL on OCT. RESULTS: A total of 182 eyes of 115 patients (63 women, mean age 65 years) were included in this study. The disease was bilateral in 81 patients (70%), and mean baseline visual acuity was 0.2 ± 0.89 logMAR (Snellen equivalent, 20/32). At baseline, 38 patients (33%) presented with isolated ocular involvement, 54 (45%) with associated central nervous system involvement, and 11 (10%) with other systemic lymphomatous involvement; an additional 12 patients (10%) presented with central nervous system and other systemic involvement. On OCT, tumor infiltration was identified in various retinal layers, including lesions in the subretinal pigment epithelium compartment (91% of eyes), the subretinal compartment (43% of eyes), and the intraretinal compartment (7% of eyes). OCT analysis of eyes with VRL identified 3 main regions of retinal infiltration. Subretinal pigment epithelium location, with or without subretinal infiltration, was the most common pattern of involvement and isolated intraretinal infiltration was the least.
UR - http://www.scopus.com/inward/record.url?scp=85123951164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123951164&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2021.11.023
DO - 10.1016/j.ajo.2021.11.023
M3 - Article
C2 - 34843686
AN - SCOPUS:85123951164
SN - 0002-9394
VL - 238
SP - 16
EP - 26
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -